01:40 PM EDT, 05/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our 12-month target to $69 from $102, 21.6x our 2025 EPS estimate, a discount to GMED's historical forward average due to soft sales in Q1. We lower our 2025 EPS view to $3.19 from $3.46 and 2026's to $3.72 from $3.96. Q1 EPS of $0.68 vs. $0.63, was a $0.06 consensus miss. Enabling Technologies (ET) had a difficult Q1, with sales -31% Y/Y due to less deal closures and temporary integration-related supply chain disruptions. However, we note ET is the smallest segment, contributing only 5%-6% of GMED's total sales. Despite the sales headwinds, profitability improved with operating margin +430 bps Y/Y to 29.7%. Further, FCF of $141.2M ($23.8M last year), helped GMED to pay off the remaining $450M of debt assumed from the NuVasive merger and return to a debt-free status. GMED lowered its 2025 EPS guidance by $0.10 to a $3.15 midpoint. Our revised opinion is due to the weakening trend seen in ET, though longer term we think the strong balance sheet and NuVasive synergies position GMED well to drive growth.